Q3 Earnings Estimate for ASMB Issued By HC Wainwright

Key Points

• HC Wainwright predicts that Assembly Biosciences will report Q3 2025 earnings of ($0.50) per share, maintaining a "Buy" rating with a price target of $50.00.
• The company recently reported a Q2 loss of ($1.33) EPS, exceeding expectations with $9.63 million in revenue compared to the forecast of $5.30 million.
• Hedge funds have shown increasing interest in Assembly Biosciences, with JPMorgan Chase & Co. boosting their stake by 225.6% during the last quarter.

Assembly Biosciences, Inc. (NASDAQ:ASMB - Free Report) - HC Wainwright issued their Q3 2025 earnings estimates for Assembly Biosciences in a research report issued to clients and investors on Monday, August 18th. HC Wainwright analyst P. Trucchio expects that the biopharmaceutical company will post earnings of ($0.50) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $50.00 target price on the stock. The consensus estimate for Assembly Biosciences' current full-year earnings is ($6.87) per share. HC Wainwright also issued estimates for Assembly Biosciences' Q4 2025 earnings at ($0.51) EPS, FY2025 earnings at ($2.93) EPS, Q1 2026 earnings at ($0.51) EPS, Q2 2026 earnings at ($0.50) EPS, Q3 2026 earnings at $0.87 EPS, Q4 2026 earnings at $0.86 EPS, FY2026 earnings at ($2.75) EPS, FY2027 earnings at $1.67 EPS, FY2028 earnings at ($1.34) EPS and FY2029 earnings at $3.07 EPS.

Separately, Zacks Research upgraded shares of Assembly Biosciences to a "hold" rating in a report on Tuesday, August 19th. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $38.67.

Assembly Biosciences Trading Up 1.1%

NASDAQ ASMB traded up $0.28 on Wednesday, hitting $26.93. 101,414 shares of the company's stock were exchanged, compared to its average volume of 122,644. The stock has a 50-day moving average of $19.80 and a 200-day moving average of $14.77. The stock has a market cap of $206.61 million, a price-to-earnings ratio of -4.83 and a beta of 0.64. Assembly Biosciences has a 52 week low of $7.75 and a 52 week high of $27.17.

Assembly Biosciences (NASDAQ:ASMB - Get Free Report) last released its earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($1.33) earnings per share for the quarter, topping the consensus estimate of ($1.73) by $0.40. Assembly Biosciences had a negative return on equity of 149.01% and a negative net margin of 117.20%.The firm had revenue of $9.63 million during the quarter, compared to analysts' expectations of $5.30 million.

Institutional Trading of Assembly Biosciences

Several institutional investors have recently modified their holdings of ASMB. American Century Companies Inc. bought a new stake in shares of Assembly Biosciences in the first quarter worth $113,000. Palumbo Wealth Management LLC grew its stake in shares of Assembly Biosciences by 57.4% in the first quarter. Palumbo Wealth Management LLC now owns 17,986 shares of the biopharmaceutical company's stock worth $172,000 after purchasing an additional 6,559 shares during the last quarter. JPMorgan Chase & Co. grew its stake in shares of Assembly Biosciences by 225.6% in the fourth quarter. JPMorgan Chase & Co. now owns 11,427 shares of the biopharmaceutical company's stock worth $180,000 after purchasing an additional 7,918 shares during the last quarter. Acadian Asset Management LLC grew its stake in shares of Assembly Biosciences by 42.1% in the first quarter. Acadian Asset Management LLC now owns 23,027 shares of the biopharmaceutical company's stock worth $219,000 after purchasing an additional 6,823 shares during the last quarter. Finally, Marshall Wace LLP grew its stake in shares of Assembly Biosciences by 16.5% in the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company's stock worth $234,000 after purchasing an additional 2,098 shares during the last quarter. Institutional investors own 19.92% of the company's stock.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.